Ernexa Therapeutics Inc. — Director's Dealing 2021

Jul 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Brooklyn ImmunoTherapeutics, Inc. (BTX)
CIK: 0000748592
Period of Report: 2021-07-15

Reporting Person: Sial Jay (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-15	Stock Option	$10.31	A	71000	Acquired	2031-07-15	Common Stock (71000)	Direct
2021-07-15	Restricted Stock Unit	$	A	35700	Acquired	2031-07-15	Common Stock (35700)	Direct

Footnotes

F1: The option vests and becomes exercisable over four years, with twenty-five percent of the shares covered thereby vesting on July 15, 2022, and 1/36 of the remaining shares covered thereby vesting on the 15th day of each calendar month from August 2022 through July 15, 2025, subject to continued service through each vesting date.

F2: Each restricted stock unit represents a contingent right to receive one share of common stock.

F3: The RSU Grant vests and becomes exercisable in four equal installments on July 15 of each of 2022, 2023, 2024 and 2025, provided that it shall vest in full immediately prior to a change in control (as defined in Mr. Sial's Executive Employment Agreement, dated as of July 6, 2021 and effective July 15, 2021), subject to continued service through each vesting date.